Hansoh Pharmaceutical Group Company Limited (HNSPF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Hansoh Pharmaceutical Group Company Limited $4.68, price $4.25, upside +10.0%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Hansoh Pharmaceutical Group Company Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
41‑month range $1.36 – $4.86 · fair‑value band $3.27 – $6.07 · the $4.25 price screens below the $4.68 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow Hansoh Pharmaceutical Group Company in your weekly email
Every Wednesday you see whether Hansoh Pharmaceutical Group Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China.
Show more
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.
Stock analysis
Hansoh Pharmaceutical Group Company Limited (HNSPF) currently trades at $4.25, while our model-based Fair Value estimate is $4.68, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $4.10 per share, and 6 of the 24 models we run sit above the $4.25 price.
Bear case: the Asset-Based group reads lowest at $0.5800, and 18 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $3.27 (bear) to $6.07 (bull), the price of $4.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Hansoh Pharmaceutical Group Company Limited reported revenue of 15.0B CNY in FY2025 versus 9.9B CNY in FY2021, a compound +10.9%/yr. Reported net income was 5.6B CNY in FY2025, compounding +19.6%/yr from FY2021.
Key figures
Market cap $25.7B · P/E ratio 30.4 · P/S ratio 11.2 · EPS (TTM) $0.1400 · Dividend yield 9.1% · Net margin 37.0% · Return on equity 17.4% · Return on assets (EBIT) 11.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 10%, HNSPF screens cheaper than that median.
Fair Value models
Bear $3.27Fair Value $4.68Bull $6.07
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+22.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+26.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.2%
Dividend (yield on the price)9.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.33% → 37%
2025 sits 66% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +5.6% a year for the price and +7.4% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (15 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Hansoh Pharmaceutical Group Company Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+8.0% · Above median
Profitability
Return on equity (TTM)17.4% · Top 25%
Return on assets9.4% · Top 25%
Net margin (TTM)37.0% · Top 25%
Operating margin (TTM)29.6% · Top 25%
Growth and dividend
Revenue growth32.0% · Top 25%
Dividend yield (TTM)9.1% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hansoh Pharmaceutical Group Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/HNSPF
Frequently asked questions
Is Hansoh Pharmaceutical Group Company Limited (HNSPF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $4.68 versus the last price from Sep 25, 2026 of $4.25, about +10% upside (undervalued).
What is the fair value of HNSPF?
Our model-based fair value for Hansoh Pharmaceutical Group Company Limited is $4.68 (as of Oct 3, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $4.25.
What is the quality score of HNSPF?
Hansoh Pharmaceutical Group Company Limited has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hansoh Pharmaceutical Group Company Limited (HNSPF)?
Our model-based price target is the fair value of $4.68 (as of Oct 3, 2026) from 24 valuation models. Cautious scenario $3.27, optimistic scenario $6.07. It is a calculation from audited fundamentals, not an analyst target.
What is the Hansoh Pharmaceutical Group Company Limited stock forecast for 2026?
Our models put fair value at $4.68, about +10% upside versus the last price from Sep 25, 2026 of $4.25 (undervalued). Cautious scenario $3.27, optimistic scenario $6.07. The calculation is refreshed regularly with new filings.
What is the revenue of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
Hansoh Pharmaceutical Group Company Limited reported trailing-twelve-month revenue of about 15.0B CNY (latest available figure, as of Oct 3, 2026).
Does Hansoh Pharmaceutical Group Company Limited pay a dividend?
Hansoh Pharmaceutical Group Company Limited currently shows a dividend yield of about 9.13% relative to its recent price (as of Oct 3, 2026).
What growth is priced into Hansoh Pharmaceutical Group Company Limited (HNSPF)?
For today's price to be fair in a discounted-cash-flow model, Hansoh Pharmaceutical Group Company Limited would have to grow free cash flow by +7.3 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.6 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of HNSPF use?
Our models discount Hansoh Pharmaceutical Group Company Limited at 8.1 %: a base by market capitalisation (large), damped by beta 0.52, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hansoh Pharmaceutical Group Company Limited that is +7.3 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Hansoh Pharmaceutical Group Company Limited (HNSPF) delivered so far?
Over the past 5 years revenue at Hansoh Pharmaceutical Group Company Limited grew +11.6 % a year. The price currently implies +7.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hansoh Pharmaceutical Group Company Limited (HNSPF) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Hansoh Pharmaceutical Group Company Limited (+7.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
The free-cash-flow yield on the price is 3.62 %: that much free cash flow Hansoh Pharmaceutical Group Company Limited produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hansoh Pharmaceutical Group Company Limited it is $4.68 per share (as of Oct 3, 2026), against a price of $4.25. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Hansoh Pharmaceutical Group Company Limited stock overvalued or undervalued in 2026?
As of Oct 3, 2026, HNSPF trades below its calculated fair value: price $4.25, fair value $4.68, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HNSPF?
No. The price is what the market pays today ($4.25); the fair value is what the company's own numbers justify ($4.68). For Hansoh Pharmaceutical Group Company Limited the two are $0.4250 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hansoh Pharmaceutical Group Company Limited worth?
The market values Hansoh Pharmaceutical Group Company Limited at about $25.7B (market capitalisation, as of Oct 3, 2026). Per share that is $4.25; our models calculate a fair value of $4.68 per share.
What do the bullish and bearish scenarios say about HNSPF?
Our models span a range for Hansoh Pharmaceutical Group Company Limited: cautious scenario $3.27, base $4.68, optimistic $6.07 per share (as of Oct 3, 2026, price $4.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HNSPF?
Hansoh Pharmaceutical Group Company Limited trades at a price-to-earnings ratio of 30.4 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.68 is built from several models across several years. Other multiples: P/B 4.9, P/S 11.5, EV/EBITDA 24.4.
How solid is the balance sheet of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
Balance-sheet figures for Hansoh Pharmaceutical Group Company Limited (as of Oct 3, 2026): return on equity 17.4%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is HNSPF from its 52-week high?
Hansoh Pharmaceutical Group Company Limited trades at $4.25, about 13% below its 52-week high of $4.86 and 18% above the low of $3.60 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $4.68 is for.
Which stocks are comparable to Hansoh Pharmaceutical Group Company Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hansoh Pharmaceutical Group Company Limited stock attractive at the current price?
The data as of Oct 3, 2026: price $4.25, calculated fair value $4.68 (+10%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HNSPF calculated?
We run Hansoh Pharmaceutical Group Company Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.68, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Hansoh Pharmaceutical Group Company Limited currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
The latest price we hold is from Sep 25, 2026 and stands at $4.25. Our model-based fair value is $4.68, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hansoh Pharmaceutical Group Company Limited right now?
A fairly wide model range ($3.27 to $6.07) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Hansoh Pharmaceutical Group Company Limited
How large is the market capitalisation of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
The market capitalisation of Hansoh Pharmaceutical Group Company Limited is $25.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
The price-to-sales ratio of Hansoh Pharmaceutical Group Company Limited is 11.2 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
Earnings per share at Hansoh Pharmaceutical Group Company Limited are $0.1400 (price ÷ EPS = P/E 30.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
The dividend yield of Hansoh Pharmaceutical Group Company Limited is 9.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
The net margin of Hansoh Pharmaceutical Group Company Limited is 37.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
The return on equity (ROE) of Hansoh Pharmaceutical Group Company Limited is 17.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
On an EBIT basis the return on assets of Hansoh Pharmaceutical Group Company Limited is 11.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hansoh Pharmaceutical Group Company Limited (HNSPF)?
The operating margin of Hansoh Pharmaceutical Group Company Limited is 29.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hansoh Pharmaceutical Group Company Limited (HNSPF)?
Revenue at Hansoh Pharmaceutical Group Company Limited is growing +32.0% versus a year earlier (3y avg +17.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hansoh Pharmaceutical Group Company Limited (HNSPF)?
Earnings per share at Hansoh Pharmaceutical Group Company Limited are growing +45.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hansoh Pharmaceutical Group Company Limited (HNSPF) carry?
The net debt of Hansoh Pharmaceutical Group Company Limited is 1.6B CNY (fiscal year 2022, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hansoh Pharmaceutical Group Company Limited in the live analysis
One click puts Hansoh Pharmaceutical Group Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Oct 3, 2026